Drug results: 2

avutometinib Avutometinib is a reversible inhibitor of RAF kinases and MEK1/2. Avutometinib inhibits RAF/MEK pathway signaling by binding to RAF kinases and MEK1/2, resulting in inhibition of phosphorylation of downstream extracellular signal-related kinase (ERK). Avutometinib in combination with defactinib enhanced inhibition of cell proliferation in vitro and anti-tumor activity in mouse tumor models including LGSOC.
defactinib Defactinib is an inhibitor of focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2). FAK and PYK2 are non-receptor tyrosine kinases that regulate cellular signaling pathways involved in cell proliferation, survival, migration, and invasion. Defactinib inhibited FAK autophosphorylation in cancer cells in vitro and in mouse xenograft models. Avutometinib in combination with defactinib enhanced inhibition of cell proliferation in vitro and antitumor activity in mouse tumor models including LGSOC.

DrugCentral Search Overview